The prognostic role of the cancer stem cell marker CD44 in ovarian cancer: a meta-analysis

Table 1 Characteristics of the included studies

Study	Patient’s country	Ethnicity	Year	Time of collection	Pathological stage	Number of patients	Age in years	Follow-up months	Cut-off for CD44 positive (% staining)	Survival analysis	Subtypes of the CD44 family	Method
Ross et al.	USA	Caucasian	2001	1991–1995	I–IV	101	30–85	70	>10	OS	CD44s	IHC
Cho et al.	Korea	Asian	2006	ND	I–III	158	ND	112	>50	OS	CD44s	IHC
Zhang et al.	China	Asian	2013	1990–2007	I–IV	483	22–89	120	>25	OS; DFS	CD44s	IHC
Zhong et al.	China	Asian	2001	1993–1996	I–IV	55	ND	ND	>10	ND	CD44v6	IHC
Rodríguez et al.	USA	Caucasian	2003	1990–1996	I–IV	142	ND	50	>50	OS; DFS	CD44v6	IHC
Hong et al.	Korea	Asian	2006	1997–2004	I–IV	65	25–74	ND	>10	ND	CD44v6	IHC
Xu et al.	China	Asian	2009	2005–2008	I–IV	63	26–80	ND	>5	ND	CD44v6	IHC
Shi et al.	China	Asian	2013	2010–2011	I–III	45	ND	ND	>25	ND	CD44v6	IHC
Tjhay et al.	Japen	Asian	2015	2002–2012	ND	59	37–82	140	>10	OS	CD44v6	IHC
Sillanpaa et al.	Finland	Caucasian	2003	1976–1992	I–IV	445	ND	237	>10	OS; DFS	CD44	IHC
Chen et al.	China	Asian	2009	2001–2007	I–IV	120	40–70	56	>25	DFS	CD44	IHC
Jiang et al.	China	Asian	2010	2007–2008	I–IV	33	33–74	ND	>50	ND	CD44	IHC
Gao et al.	USA	Caucasian	2015	ND	I–IV	26	ND	150	>25	OS; DFS	CD44	IHC
Steffensen et al.	Denmark	Caucasian	2011	ND	I–IV	109	32–79	40	>20	ND	CD44	IHC
Liu et al.	USA	Caucasian	2012	2006–2007	I–IV	33	44–86	60	>5	OS	CD44	IHC
Li et al.	China	Asian	2012	2007–2008	I–IV	46	ND	ND	>10	ND	CD44	IHC
Wang et al.	China	Asian	2015	2006–2012	I–IV	86	29–73	94	>50	OS	CD44	IHC
Zhu et al.	USA	Caucasian	2015	2006–2010	I–IV	92	24–78	84	>25	OS	CD44	IHC

IHC immunohistochemistry, OS overall survival, DFS disease-free survival, ND not document

ISSN: 1475-2867